Experts share their perspective on the optimal management of chronic lymphocytic leukemia in light of recent clinical data for novel targeted therapies.
EP. 1: Revolutionizing the Management of Chronic Lymphocytic Leukemia
A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.
EP. 2: Frontline BTK Inhibition in CLL: 7-Year Follow-up Data From RESONATE-2
Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.
EP. 3: 4-Year Follow-up Data From ELEVATE-TN: Frontline Acalabrutinib in CLL
Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.
EP. 4: Head-to-Head Analysis of Acalabrutinib Vs Ibrutinib in Previously Treated CLL
Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.
EP. 5: Optimal Toxicity Management With BTK Inhibitors in CLL
Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.
EP. 6: Moving the Dial on CLL Management: Sequencing Strategies and Unmet Needs
Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.
EP. 7: The Evolution of CLL Treatment
Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.
EP. 8: Rationale and Use of BTK Inhibitors as Initial Treatment for CLL
A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.
EP. 9: Frontline BTKi Therapy in CLL: The ELEVATE-TN Study 4-Year Follow-up
Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.
EP. 10: Acalabrutinib vs Ibrutinib: Head-to-Head Data in Previously Treated CLL
Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.
EP. 11: Optimal Treatment Strategies for Chronic Lymphocytic Leukemia
Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.
EP. 12: Looking Toward the Future of CLL Management
An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.